The Association Between Modified Albumin-Bilirubin (mALBI) and Survival in Advanced Non-small Cell Lung Cancer...

Area of Science:

• Oncology
• Immunotherapy
• Biomarker Discovery

Background:

• Advanced non-small cell lung cancer (NSCLC) poses significant treatment challenges.
• Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized NSCLC treatment.
• Predictive biomarkers are crucial for optimizing immunotherapy efficacy and patient outcomes.

Purpose of the Study:

• To evaluate the clinical utility of the modified albumin-bilirubin (mALBI) grade.
• To assess the mALBI grade's ability to predict survival in advanced NSCLC patients undergoing immunotherapy.
• To explore the association between mALBI grades and overall survival (OS) and treatment response.

Main Methods:

• Retrospective cohort study design.
• Inclusion of advanced NSCLC patients treated with ICIs between January 2020 and May 2022.
• Analysis of baseline and dynamic mALBI grades in relation to OS and treatment response.

Main Results:

• Patients with higher baseline mALBI grades (1 and 2a) demonstrated significantly longer median OS (12.83 months) compared to lower grades (2b and 3; 3.2 months).
• Dynamic mALBI grading also revealed superior OS for grades 1 and 2a (13.27 months) versus grades 2b and 3 (5 months; p<0.01).
• The study included 67 patients, with a median age of 63 years and 85.1% males.

Conclusions:

• The modified albumin-bilirubin (mALBI) grade is a potential dynamic biomarker for prognosis prediction in advanced NSCLC patients treated with immunotherapy.
• mALBI grade can help stratify patients based on predicted survival outcomes.
• Further research is warranted to validate mALBI as a routine predictive tool in NSCLC immunotherapy.